医学
奥沙利铂
内科学
胃肠病学
养生
恶心
中性粒细胞减少症
卵巢癌
化疗
人口
临床研究阶段
外科
癌症
结直肠癌
环境卫生
作者
Maria Rosaria Valerio,Pierosandro Tagliaferri,Francesco Raspagliesi,Fabio Fulfaro,Giuseppe Badalamenti,Carlo Arcara,Giuseppe Cicero,Antonio Russo,Salvatore Venuta,Giovanni Guarneri,N. Gebbia
出处
期刊:International Journal of Gynecological Cancer
[BMJ]
日期:2006-02-01
卷期号:16 (S1): 79-85
被引量:15
标识
DOI:10.1111/j.1525-1438.2006.00324.x
摘要
We carried out a phase II nonrandomized study to examine the level of activity of oxaliplatin, pegylated liposomal doxorubicin, and cyclophosphamide in a patient population with relapsed ovarian cancer pretreated with platinum derivatives and paclitaxel. Patients received oxaliplatin (85 mg/m2), pegylated liposomal doxorubicin (30 mg/m2), and cyclophosphamide (750 mg/m2). A total of 49 patients (39 assessable for toxicity and response) were enrolled in this trial. Neutropenia grade 3 was observed in six patients (15%) and anemia grade 3 in one patient (0.2%). Fatigue grade 1-2 occurred in 26 patients (66%), nausea/vomiting grade 1 in 23 patients (58%), and alopecia grade 1-2 in 19 patients (48%). Twenty-one (53%) patients experienced grade 1-2 peripheral neuropathy. The overall response rate was 46% (95% CI 23.6-68.7). Median progression-free survival was 28 weeks (range 12-52 weeks) and median survival was 45 weeks (range 26-136+ weeks). The mean duration of response was 34 weeks (range 16-52 weeks). In platinum-resistant and -refractory ovarian cancer patients, the overall response rate was 37% (CI 95% 14.4-60.8) with a progression-free survival of 28 weeks (range 12-52 weeks) and a median survival of 42 weeks (range 28-84 weeks). This combination chemotherapy is generally well tolerated and is an active second-line regimen against ovarian cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI